Adma Biologics Stock News

Goldman Sachs Group Inc. reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 62.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,805 shares of the biotechnology companys stock after selling 232,591 shares during the period. Goldman Sachs Group Inc. [] The post Goldman Sachs Group Inc. Sells 232,591 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) appeared first on ETF Daily News .

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Community Health Systems' (CYH) cost-control initiatives are likely to lower costs to a great extent and boost the bottom line.

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin

Given this backdrop, investors likely want to consider adding stocks in December and heading into 2022. Today, we utilized a Zacks screen to find highly-ranked stocks trading for under $10 a share...

Given this backdrop, investors likely want to consider adding stocks in December and heading into 2022. Today, we utilized a Zacks screen to find highly-ranked stocks trading for under $10 a share.

Zacks Investment Research downgraded shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research report report published on Thursday morning, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of []

Zacks Investment Research cut shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of []

Meridian Wealth Management LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 206,000 shares of the biotechnology companys stock after acquiring an additional 42,000 shares during the period. Meridian Wealth []

ADMA Biologics Inc. (NASDAQ:ADMA) traded at $1.45 at close of the session on Monday, 11/29/21, made a downward move of 0.00% on its previous days price. Looking at the stock we see that its previous close was $1.45 and the beta (5Y monthly) reads 1.33 with the days price range being $1.41 $1.465. In ADMA Biologics Inc. (NASDAQ: ADMA) Is Down 0.00% Is It Capable Of A Rally? Read More »

Zacks Investment Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. Zacks Investment Research currently has $1.50 target price on the biotechnology companys stock. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures [] The post Zacks Investment Research Upgrades ADMA Biologics (NASDAQ:ADMA) to Buy appeared first on ETF Daily News .

Renaissance Technologies LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 175,626 shares of the biotechnology companys stock, valued at approximately $281,000. Renaissance Technologies LLC owned approximately 0.14% of ADMA Biologics []

Zacks Investment Research cut shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a report issued on Monday, Zacks.com reports. According to Zacks, “ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. […]

Brokerages forecast that ADMA Biologics, Inc. (NASDAQ:ADMA) will announce $21.93 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for ADMA Biologics earnings. The lowest sales estimate is $21.40 million and the highest is $22.60 million. ADMA Biologics reported sales of $13.96 million in the same quarter []